Austin-based Asuragen is spinning off its miRNA therapeutic intellectual property into a new company and seeding it with $3 million in cash. Working with Yale University researchers, Mirna will pursue the development of synthetic miRNA to beef up the presence of these small RNAs. Low levels of miRNA are recorded in a variety of cancers, and adding substitute miRNA may prove to be a significant new development field.
"The discovery of miRNAs represents a paradigm changing event in biology and medicine of a magnitude that only occurs once every decade or two," said Matt Winkler CEO/CSO of Asuragen. "They likely will become a major new class of drugs."
- check out the press release